Wednesday , November 6 2024
Home / The Angry Bear / Reporting from Germany: “Welt am Sonntag”

Reporting from Germany: “Welt am Sonntag”

Summary:
Welt am Sonntag is reporting our honorable President is attempting to bribe lure a German company CureVac to develop a vaccine  to be used only in the US. Germany’s Health Ministry confirmed a report in the newspaper “Welt am Sonntag”, which said President Donald Trump had offered bribes funds to lure the German company CureVac to the United States, and the German government was making counter-offers to tempt it to stay. Welt am Sonntag quoted an unidentified German government source as saying Trump was trying to secure the scientists’ work exclusively, and would do anything to get a vaccine for the United States, “but only for the United States.” CureVac’s chief production officer and co-founder Florian von der Muelbe told Reuters the company had started

Topics:
run75441 considers the following as important: , ,

This could be interesting, too:

NewDealdemocrat writes Real GDP for Q3 nicely positive, but long leading components mediocre to negative for the second quarter in a row

Joel Eissenberg writes Healthcare and the 2024 presidential election

Angry Bear writes Title 8 Apprehensions, Office of Field Operations (OFO) Title 8 Inadmissible, and Title 42 Expulsions

Joel Eissenberg writes The business of aging

Welt am Sonntag is reporting our honorable President is attempting to bribe lure a German company CureVac to develop a vaccine  to be used only in the US.

Germany’s Health Ministry confirmed a report in the newspaper “Welt am Sonntag”, which said President Donald Trump had offered bribes funds to lure the German company CureVac to the United States, and the German government was making counter-offers to tempt it to stay.

Welt am Sonntag quoted an unidentified German government source as saying Trump was trying to secure the scientists’ work exclusively, and would do anything to get a vaccine for the United States, “but only for the United States.”

CureVac’s chief production officer and co-founder Florian von der Muelbe told Reuters the company had started with multitude coronavirus vaccine candidates and was now selecting the best two to send into clinical trials.

The privately-held company based in Tübingen, Germany hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans.

Earlier this month CureVac CEO Daniel Menichella met Trump, Pence, members of the White House Coronavirus Task Force, and senior representatives of pharmaceutical and biotech companies to discuss a vaccine.

Professor of Health Economics and Epidemiology Karl Lauterbach, a senior lawmaker with the Social Democrats and a junior partner in Chancellor Angela Merkel’s coalition stated:

“The exclusive sale of a possible vaccine to the USA must be prevented by all means. Capitalism has limits.”

Germany tries to stop US from luring away firm seeking coronavirus vaccine, CNBC, March 15, 2020

About run75441

Leave a Reply

Your email address will not be published. Required fields are marked *